Is ALMR a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Consumable pull-through per instrument, with revenue (ttm) at ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year. The bear case rests on almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Analysts covering it are spread from $31.00 to $35.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $31.00, -15.2% from the $36.57 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Consumable pull-through per instrument. Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. The most optimistic analyst target on ALMR is $35.00, -4.3% from the $36.57 price. That figure is only reachable if this thesis works close to its best case.

Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation leaves little slack, with the shares near 20 times guided 2026 revenue while the company loses money each quarter, so a single soft guide can reprice the stock hard in either direction. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which can put additional shares into a thinly traded float in the fourth quarter. The most pessimistic published target is $31.00, -15.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Proteomics tools maker selling the ARGO HT instrument and NULISAseq assay panels to research labs on a razor-and-blade model.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Consumable pull-through per instrument) stalling in the reported numbers rather than in the narrative, the risk above (almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It sells laboratory instruments and the reagent kits that run on them, aimed at measuring proteins in blood and other biofluids at very low concentrations. The ARGO HT system automates the workflow, and NULISAseq panels such as Neuro 220, Inflammation 250 and Immune 340 are the consumables that generate recurring revenue. Customers are research labs in academia, biotech and pharma, more than 300 of them across 25 countries.

NULISA is Alamar's assay chemistry, which combines antibody-based protein capture with a sequencing readout instead of the fluorescence or colorimetric detection a conventional immunoassay uses. The point is sensitivity: it targets proteins that circulate at concentrations standard ELISA methods cannot reliably read, which is what makes blood-based measurement of neurological markers practical. That sensitivity claim is also what competitors attack, so independent benchmarking studies carry weight in this market.

ALMR trades on the Nasdaq Global Select Market, so any US broker can buy it in dollars during normal market hours, including fractionally at brokers that support fractional orders. It listed on April 17, 2026 after pricing its IPO at $17 a share. Because it is a recent, small-cap listing with a limited float, spreads and daily swings tend to be wider than in a large-cap stock.